Monoclonal Antibodies in Headache

1. Front Matter

   Pages i-x

   PDF

2. The CGRP Family of Neuropeptides and their Receptors in the Trigeminovascular System

   • Lars Edvinsson, Karin Warfvinge

   Pages 1-12

3. Pharmacology; Where Do the mAbs Act, Gepants Versus mAbs

   • Alejandro Labastida-Ramírez

   Pages 13-23

4. Monoclonal Antibody Biology

   • Hsiangkuo Yuan, Stephen D. Silberstein

   Pages 25-42

5. Guidelines for Clinical Trials

   • Raffaele Ornello, Eleonora De Matteis, Simona Sacco

   Pages 43-54

6. Human Models

   • Samaira Younis, Thien Phu Do, Messoud Ashina

   Pages 55-68

7. CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders

   • Mengya Wang, Anne-Sophie Wattiez, Andrew F. Russo

   Pages 69-97

8. Galcanezumab

   • Uwe Reuter, Bianca Raffaelli

   Pages 99-108

9. Eptinezumab

   • Hsiangkuo Yuan, Stephen D. Silberstein

   Pages 109-119

10. Erenumab

    • Thien Phu Do, Samaira Younis, Messoud Ashina

    Pages 121-129

11. Fremanezumab

    • Luana Lionetto, Matilde Capi, Valerio De Angelis, Paolo Martelletti

    Pages 131-136

12. Potential Side Effects and Pregnancy

    • Eloísa Rubio-Beltrán

    Pages 137-149

13. Real-World Data, Clinical Practice So Far

    • Eleonora De Matteis, Raffaele Ornello, Simona Sacco

    Pages 151-166

14. Migraine Versus Cluster Headache and Potential Other Indications

    • Matilde Capi, Luana Lionetto, Valerio De Angelis, Paolo Martelletti

    Pages 167-172

Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.

• Migraine
• Cluster headache
• CGRP
• Galcanezumab
• Eptinezumab
• Erenumab
• Fremanezumab
• psychopharmacology

• Internal Medicine, Erasmus University Medical Center, Rotterdam, Zuid-Holland, The Netherlands

  Antoinette Maassen van den Brink

• Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy

  Paolo Martelletti

Antoinette Maassen van den Brink is an Associate Professor of Pharmacology at the Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.  Her main focus is on the neurovascular aspects of migraine, with a special interest in the impact of female sex hormones on the disease’s neurovascular pharmacology. She is a board member of the Dutch Society for Gender & Health, Dutch Pharmacological Society, the Federation of European Pharmacological Societies, the Dutch Headache Society, and the European Headache Federation.

Paolo Martelletti has been an Associate Professor of Internal Medicine at the University 'La Sapienza' of Rome since 2005 and Director of the Regional Reference Centre for Headaches at Sant'Andrea Hospital in Rome, Italy, since 2003. After extensive research activities in the fields of internal medicine, cephalalgias, and pain management since 1980, he is now exploring new research avenues for the study of factors for chronicity, comorbidities, and aspects of health economics in primary headaches; elaborating rehabilitation protocols in patients with secondary headache as a consequence of medication abuse; and studying innovative therapies for the acute treatment and prophylaxis of primary headaches. He is a series editor of the Springer Headache series, Editor in Chief of the Journal of Headache and Pain, and Section Editor of Comprehensive Clinical Medicine.

Policies and ethics